Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Enrollment completed in Maxim's malginant melanoma phase III trial

Feb. 9, 1999

Ligand receives FDA approval for Ontak as CTCL treatment

Feb. 8, 1999

ImmunoGen and SB enter agreement for colorectal cancer treatment

Feb. 4, 1999

Phase I clinical trial of novel cervical dysplasia Rx from StressGen

Feb. 3, 1999

SWOG phase II study of safety and efficacy of rhIL-4 in malignant melanoma

Jan. 25, 1999

Polish authorities allow phase II testing of Multikine

Jan. 15, 1999

Health Canada approves new indication for Proleukin

Jan. 12, 1999

Proleukin receives orphan drug status for two new indications

Jan. 7, 1999

Anticancer immunotoxin available for licensing from NIH

Jan. 4, 1999

Promising phase III trial results presented for Coulter's lead cancer therapy

Dec. 29, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...